VX-121/Tezacaftor/Deutivacaftor

· Vertex Pharmaceuticals Incorporated

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VX-121/Tezacaftor/Deutivacaftor, covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age [Phase 3]

See pricing